Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies
Introduction: Since 2016, several therapies have been approved for treating atopic dermatitis (AD) in Singapore, including biologics, oral Janus kinase (JAK) inhibitors and topical crisaborole. This study supplements the 2016 Singapore treatment guidelines for AD, focusing on newer therapies for mo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academy of Medicine Singapore
2024-11-01
|
| Series: | Annals, Academy of Medicine, Singapore |
| Online Access: | https://annals.edu.sg/updated-consensus-guidelines-for-management-of-moderate-to-severe-atopic-dermatitis-in-singapore-integrating-biologics-janus-kinase-inhibitors-and-conventional-therapies/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846143130918715392 |
|---|---|
| author | Yik Weng Yew Uma Alagappan Derrick Aw Suyien Chandran Karen JL Choo Roland Chu Hong Yi Koh Mark Jean Aan Koh Shan Xian Lee Ching Yin Neoh Siyun Lucinda Tan Mark Tang Yong-Kwang Tay Seth Francis-Graham Andrew Lim Haur Yueh Lee |
| author_facet | Yik Weng Yew Uma Alagappan Derrick Aw Suyien Chandran Karen JL Choo Roland Chu Hong Yi Koh Mark Jean Aan Koh Shan Xian Lee Ching Yin Neoh Siyun Lucinda Tan Mark Tang Yong-Kwang Tay Seth Francis-Graham Andrew Lim Haur Yueh Lee |
| author_sort | Yik Weng Yew |
| collection | DOAJ |
| description |
Introduction: Since 2016, several therapies have been approved for treating atopic dermatitis (AD) in Singapore, including biologics, oral Janus kinase (JAK) inhibitors and topical crisaborole. This study supplements the 2016 Singapore treatment guidelines for AD, focusing on newer therapies for moderate-to-severe disease, while revisiting older treatment regimens to accommodate changes in knowledge and practice. Method: A modified Delphi panel was held, led by 2 co-chairs. The voting expert panel consisted of 12 dermatologists experienced in managing AD in Singapore. Delphi survey rounds were conducted between 24 July and 27 October 2023. Panellists indicated their agreement with drafted statements using a 5-point Likert scale. Consensus was defined as ≥80% agreement. An expert meeting was held to facilitate the consensus process between rounds 1 and 2 of voting. Results: All expert panellists participated in both survey rounds, with a 100% response rate. Thirty-nine statements, classified into general principles, conventional treatments, biologics and JAK inhibitors, were proposed. Of these, 27 statements reached consensus at the end of round 1. After the expert meeting, 17 statements were included in round 2, of which 16 statements reached consensus. One statement did not reach consensus. Key updates are the inclusion of dupilumab and JAK inhibitors as potential first-line treatments for moderate-to-severe AD, in certain populations. Conclusion: This modified Delphi study generated consensus among Singapore dermatology experts, to update treatment guidelines in moderate-to-severe atopic dermatitis. The consensus statements developed are intended to supplement the 2016 Singapore treatment guidelines for AD. Further revisions may be required when new evidence and/or treatments become available. |
| format | Article |
| id | doaj-art-523c06182b7c48359c036a0bca4aa56a |
| institution | Kabale University |
| issn | 2972-4066 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Academy of Medicine Singapore |
| record_format | Article |
| series | Annals, Academy of Medicine, Singapore |
| spelling | doaj-art-523c06182b7c48359c036a0bca4aa56a2024-12-03T01:17:52ZengAcademy of Medicine SingaporeAnnals, Academy of Medicine, Singapore2972-40662024-11-01531167068210.47102/annals-acadmedsg.2024158Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapiesYik Weng YewUma AlagappanDerrick AwSuyien ChandranKaren JL ChooRoland ChuHong Yi KohMark Jean Aan KohShan Xian LeeChing Yin NeohSiyun Lucinda TanMark TangYong-Kwang TaySeth Francis-GrahamAndrew LimHaur Yueh Lee Introduction: Since 2016, several therapies have been approved for treating atopic dermatitis (AD) in Singapore, including biologics, oral Janus kinase (JAK) inhibitors and topical crisaborole. This study supplements the 2016 Singapore treatment guidelines for AD, focusing on newer therapies for moderate-to-severe disease, while revisiting older treatment regimens to accommodate changes in knowledge and practice. Method: A modified Delphi panel was held, led by 2 co-chairs. The voting expert panel consisted of 12 dermatologists experienced in managing AD in Singapore. Delphi survey rounds were conducted between 24 July and 27 October 2023. Panellists indicated their agreement with drafted statements using a 5-point Likert scale. Consensus was defined as ≥80% agreement. An expert meeting was held to facilitate the consensus process between rounds 1 and 2 of voting. Results: All expert panellists participated in both survey rounds, with a 100% response rate. Thirty-nine statements, classified into general principles, conventional treatments, biologics and JAK inhibitors, were proposed. Of these, 27 statements reached consensus at the end of round 1. After the expert meeting, 17 statements were included in round 2, of which 16 statements reached consensus. One statement did not reach consensus. Key updates are the inclusion of dupilumab and JAK inhibitors as potential first-line treatments for moderate-to-severe AD, in certain populations. Conclusion: This modified Delphi study generated consensus among Singapore dermatology experts, to update treatment guidelines in moderate-to-severe atopic dermatitis. The consensus statements developed are intended to supplement the 2016 Singapore treatment guidelines for AD. Further revisions may be required when new evidence and/or treatments become available.https://annals.edu.sg/updated-consensus-guidelines-for-management-of-moderate-to-severe-atopic-dermatitis-in-singapore-integrating-biologics-janus-kinase-inhibitors-and-conventional-therapies/ |
| spellingShingle | Yik Weng Yew Uma Alagappan Derrick Aw Suyien Chandran Karen JL Choo Roland Chu Hong Yi Koh Mark Jean Aan Koh Shan Xian Lee Ching Yin Neoh Siyun Lucinda Tan Mark Tang Yong-Kwang Tay Seth Francis-Graham Andrew Lim Haur Yueh Lee Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies Annals, Academy of Medicine, Singapore |
| title | Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies |
| title_full | Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies |
| title_fullStr | Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies |
| title_full_unstemmed | Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies |
| title_short | Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies |
| title_sort | updated consensus guidelines for management of moderate to severe atopic dermatitis in singapore integrating biologics janus kinase inhibitors and conventional therapies |
| url | https://annals.edu.sg/updated-consensus-guidelines-for-management-of-moderate-to-severe-atopic-dermatitis-in-singapore-integrating-biologics-janus-kinase-inhibitors-and-conventional-therapies/ |
| work_keys_str_mv | AT yikwengyew updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT umaalagappan updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT derrickaw updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT suyienchandran updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT karenjlchoo updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT rolandchu updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT hongyikoh updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT markjeanaankoh updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT shanxianlee updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT chingyinneoh updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT siyunlucindatan updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT marktang updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT yongkwangtay updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT sethfrancisgraham updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT andrewlim updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies AT hauryuehlee updatedconsensusguidelinesformanagementofmoderatetosevereatopicdermatitisinsingaporeintegratingbiologicsjanuskinaseinhibitorsandconventionaltherapies |